Navigation Links
Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
Date:4/2/2009

NEW HAVEN, Conn., April 2 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced that its lead compound, delafloxacin, has been selected by R&D Directions editors for the 8th annual report on "100 Great Investigational Drugs," published in the March 2009 issue.

R&D Directions is a leading pharmaceutical industry magazine. Compounds selected by editors for the report, including delafloxacin, demonstrated "particular promise in a... growing therapeutic area of unmet medical need... and target disease pathways using a distinctly innovative mechanism of action."(1)

"We are honored to have our lead compound, delafloxacin, recognized by the editors of R&D Directions as one of the top 100 investigational drugs of 2009," said Susan Froshauer, PhD, President and CEO of Rib-X Pharmaceuticals. "The broad spectrum activity demonstrated by delafloxacin against a wide range of highly-resistant bacteria may offer the medical community a much needed treatment alternative for a variety of serious hospital treated infections, including complicated skin, hospital acquired pneumonia, endocarditis and others. We are proud of the work we have done at Rib-X to further the development of this compound."

A copy of the R&D Directions 100 Great Investigational Drugs of 2009 report can be viewed at http://www.rddirections.com/magazines/randd/.

About Delafloxacin

Delafloxacin, a novel, broad spectrum, next-generation fluoroquinolone, has demonstrated better activity than other quinolones against Gram-positive bacteria, including isolates of MRSA that are resistant to other quinolones. The Company recently announced positive results from a Phase 2 trial utilizing the IV formulation of delafloxacin in complicated skin and skin structure infections (cSSSI). Delafloxacin successfully completed two previous Phase 2 trials with the oral formulation. In large panel microbiological testing, the compound has been shown to be at least 32-fold more potent than levofloxacin, ciprofloxacin, gatifloxacin and moxifloxacin against quinolone-resistant MRSA (MIC90 of less than or equal to 0.5 ug/ml for delafloxacin versus > 16 ug/ml for all other quinolones) and twice as potent as daptomycin against MRSA. Delafloxacin has also been shown to be more potent than existing quinolones against a range of Gram-positive, anaerobic and Gram-negative organisms. Rib-X is currently developing both IV and oral formulations of delafloxacin for use in surgical prophylaxis and other therapeutic arenas within the over $9.9 billion hospital antibiotic market.(2)

About cSSSI

Complicated skin and skin structure infections (cSSSI) encompass a wide range of serious infections involving the deeper soft tissue, including severe cellulitis and major abscesses. These infections may occur in patients with skin ulcers or burns, as well as patients who have undergone surgery or experienced other kinds of trauma. These infections affect over one million patients in the U.S. annually and are most commonly caused by Gram-positive bacteria, specifically Staphylococcus aureus and methicillin-resistant S. aureus (MRSA).

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. In addition to delafloxacin, Rib-X is currently in Phase 2 trials with radezolid (RX-1741), an oxazolidinone that was discovered at Rib-X, as an oral/IV agent for treatment of serious Gram-positive infections. The Rx-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria and the Rx-02 discovery program is focused on developing an IV/oral macrolide active against methicillin-resistant S. aureus, multidrug-resistant Streptococcus pneumoniae and S. pyogenes. Both delafloxacin and radezolid are currently in Phase 2 clinical trials.

For more information on the Rib-X mission and the pipeline, please visit the Company website at www.rib-x.com.

(1) 100 Great Investigational Drugs; R&D Directions; March 2009

(2) Commercial and Pipeline Insight: Hospital Antibacterials - A market beyond MRSA; Datamonitor; August 24, 2007

    For further information please contact:

    Media:
    Irma Gomez-Dib
    FD Life Sciences
    Tel: 212-850-5761
    irma.gomez-dib@fd.com

    Investors:
    John Capodanno
    FD Life Sciences
    Tel: 212-850-5705
    John.capodanno@fd.com


'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
2. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
3. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
4. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
5. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
6. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
7. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
8. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
9. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
10. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
11. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016 Global Interventional Radiology ... the global interventional radiology market analyzes the current ... comprises an elaborate executive summary, including a market ... and sub-segments. The research is a combination ... the bulk of our research efforts along with ...
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... of the market in 2016 and is expected to ... attributed to a large number of surgical procedures that ... largest share in the patient temperature management market.) Patient ... reducing loss of blood during surgeries, lowering the risks ...
(Date:12/8/2016)... , Dec. 8, 2016 Allergy Diagnostics ... products and tests that are used to determine ... peanuts, milk, or drugs etc. in the samples ... the immune system. The report on global allergy ... of the market. The report consists of an ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Russ ... announced the first national #QuackGivesBack campaign which supported local breast cancer organizations during ... franchise-wide Quack Gives Back initiative, and we’re very pleased with the ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s ... groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced ... J. Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... of access for customers and employees that are both engaging and easy to ... Service Smart Technology, the software company revealed today its plans to roll out ...
(Date:12/8/2016)... ... ... STAT courier is pleased to announce that due to customer demand, as ... their presence in Dallas. One of the most exciting parts for STAT is that ... Dallas and Forth Worth market. STAT takes pride in treating their employees with integrity ...
(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the digital ... B led by Canvas Ventures . Other investors include Nokia Growth Partners (NGP) ... platform to serve more consumers who are managing chronic conditions or simply ...
Breaking Medicine News(10 mins):